Tweet on, drugmakers. Not only is Twitter use by pharma companies on the rise, but so is interest in what they've got to say. A recent survey by the Eye on FDA blog found more daily interactions on Twitter by pharma, along with a marked increase in followers versus last year.
Back when Martin Shkreli was CEO of Retrophin, he managed to grab a few headlines by buying an old rare-disease drug, Thiola, and raising the price 2000%. Now that he's on to his next company, Turing Pharmaceuticals, he's done himself one better, by buying another old drug and boosting the price 5000%.
A congressman is taking aim at perceived flaws in FDA's long-awaited, much-discussed guidance on the use of Twitter.
IBM has made another foray into healthcare research. The latest collaboration sees the tech veteran team up with Cleveland Clinic to use Watson in genomics cancer research.
The window for commenting on the FDA's draft guidance on pharma's use of Twitter and other social media slammed shut last week, leaving the agency with a stack of feedback to consider. Many of the respondents are unhappy with the draft, which was called unconstitutional and overbroad.
Having had a week to mull over the FDA's latest batch of social media guidance, some observers have concluded the agency is making a blunt statement to brand managers: Don't use Twitter.
Any brand managers eager to jump into Twitter as soon as the FDA gave the go-ahead? No such luck. Last week's social media guidance on risk disclosures may have cleared up some of the regulatory fog, but in this case, clarity isn't a positive.
The FDA continued to build its patchwork quilt of social media guidance this week with the publication of two new draft documents, one of which is the long-awaited discussion on how to use Twitter. And while the guidance places significant constraints on how biopharma can use the platform, some think the clarity it brings will prompt companies to become more active tweeters.
Authorities removed more than 19,000 ads on Facebook, Twitter and YouTube that promoted the illegal sale of medicines.
The steady flow of posts about adverse events on social media provide an interesting opportunity for the FDA to improve postmarketing safety surveillance. Yet an FDA-funded study has found that mining the data for insights is difficult, with humans still better equipped than machines to decipher chatter on Twitter.